A review of uses of health care utilization databases for epidemiologic research on therapeutics

Schneeweiß, Sebastian; Avorn, Jerry

doi:10.1016/j.jclinepi.2004.10.012

Cited by 1,073 publications

(1,045 citation statements)

References 108 publications

Supporting

Mentioning

1,032

Contrasting

Unclassified

Order By: Relevance

“…Most patients dropped out of the study because of treatment discontinuation or because they developed a study outcome; only 4.4% of the patients dropped out because of disenrollment from the PACE plan. Studies of the effect of long-term DMARD treatment are necessarily limited to highly selective patient populations with good tolerance and adherence to DMARD regimens (39). We conclude that neither confounding nor outcome misclassification is a likely explanation for the results of our study.…”

Section: Discussionmentioning

confidence: 57%

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

Schneeweiß¹,

Setoguchi²,

Weinblatt³

et al. 2007

Arthritis & Rheumatism

Self Cite

281

169

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 57%

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

Schneeweiß¹,

Setoguchi²,

Weinblatt³

et al. 2007

Arthritis & Rheumatism

Self Cite

281

169

View full text Add to dashboard Cite

show abstract

“…primary care or hospital data that are being used for patient care or administrative purposes). [91][92][93][94][95] In addition, whereas randomized trials assess the effects of a specific exposure (i.e. a particular dose of a particular drug with information about adherence) on outcomes that are sought systematically, observational studies often only assess more general associations (e.g.…”

Section: Potential To Assess Prolonged Exposure To Treatmentmentioning

confidence: 99%

“…93,[106][107][108] Biases due to differences in the ascertainment of health outcomes Observational studies of treatment effects are often based on health outcome data that have been recorded without consistent coding or validation. [92][93][94][95] Moreover, by contrast with the situation in randomized controlled trials with blinded treatment assignment (i.e. when patients and their doctors do not know whether they are taking the active treatment or a matching placebo), patients being treated in routine practice know that they are taking a particular drug, as do their doctors.…”

Section: Biases Due To Differences In Underlying Risks Of Health Outcmentioning

confidence: 99%

Interpretation of the evidence for the efficacy and safety of statin therapy

et al. 2016

View full text Add to dashboard Cite

General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms SummaryThis review is intended to help clinicians, patients and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomized controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment.Large-scale randomized trial evidence shows that statin therapy reduces the risk of heart attacks, ischaemic strokes and coronary revascularization procedures ("major vascular events") by about one quarter for each mmol/L reduction in low density lipoprotein (LDL) cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (e.g. atorvastatin 40 mg daily, costing about £2 per

show abstract

“…This study has limitations inherent to all studies utilizing administrative claims data 36, 37. Most notably, detailed clinical data are not available, which may have impacted the study results.…”

Section: Discussionmentioning

confidence: 95%

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Brown

Raissi

Han

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundRetrieval of vena cava filters (VCFs) is important for safety as complications increase with longer dwell times. This study assessed VCF retrieval rates and factors associated with retrieval in a national cohort.Methods and Results VCFs were identified by procedural codes from an administrative claims database. Patients were identified who had a VCF placement during a hospitalization from a national commercial administrative claims database. Indications for VCF placement were identified as pulmonary embolism with or without deep vein thrombosis, deep vein thrombosis only, or prophylactic. Patient demographic and clinical characteristics were included in proportional hazard regression models to find associations with early (90‐day) and 1‐year VCF retrieval. Initiation of anticoagulation and the correlation between time‐to‐retrieval and time‐to‐initiation of anticoagulation were observed. Of 54 766 patients receiving a VCF, 36.9% had pulmonary embolism, 43.9% had deep vein thrombosis only, and 19.2% had no apparent venous thromboembolism present. Over the 1 year of follow‐up, the cumulative incidence of VCF retrieval was 18.4%. Retrieval increased over time from a low of 14.0% in 2010 up to ≈24% in 2014. In adjusted time‐to‐event models, increasing age, differing regions, and some comorbidities were associated with poorer retrieval rates. Initiation of anticoagulation was poorly correlated with retrieval, with anticoagulation preceding retrieval by a median of 51 days while those without retrieval had a median of 278 days of exposure to anticoagulation.Conclusions VCF retrieval increased over the study period but remained suboptimal and was weakly correlated with anticoagulation initiation.

show abstract

A review of uses of health care utilization databases for epidemiologic research on therapeutics

Cited by 1,073 publications

References 108 publications

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

Interpretation of the evidence for the efficacy and safety of statin therapy

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Contact Info

Product

Resources

About